Evidence map›Paper›PMID 37983258›Full record

ArticlePLOS digital health2023

Fairness as an afterthought: An American perspective on fairness in model developer-clinician user collaborations.

John Banja, Judy Wawira Gichoya, Nicole Martinez-Martin, Lance A Waller, Gari D Clifford

Abstract read
In one paragraph

Article in PLOS digital health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John BanjaCenter for Ethics, Emory University, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0002-9464-3298
Judy Wawira GichoyaDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Nicole Martinez-MartinStanford University Center for Biomedical Ethics, Stanford University, Stanford, California, United States of America.
Lance A WallerDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0001-5002-8886
Gari D CliffordDepartment of Biomedical Informatics, Emory University School of Medicine, Atlanta, Georgia, United States of America.

Funding

RADX TECH - CERES NANOSCIENCE INC NANOTRAP PARTICLE MANUFACTURING75N92020C00021 · NHLBI · CERES NANOSCIENCES, LLLP · PI DUNLAP, ROSS · 2021 to 2021
$4.0M
NHLBI NIH HHS 75N92020C00008NHLBI NIH HHS 75N92020C00021
6 · The paper itself

Abstract

Numerous ethics guidelines have been handed down over the last few years on the ethical applications of machine learning models. Virtually every one of them mentions the importance of "fairness" in the development and use of these models. Unfortunately, though, these ethics documents omit providing a consensually adopted definition or characterization of fairness. As one group of authors observed, these documents treat fairness as an "afterthought" whose importance is undeniable but whose essence seems strikingly elusive. In this essay, which offers a distinctly American treatment of "fairness," we comment on a number of fairness formulations and on qualitative or statistical methods that have been encouraged to achieve fairness. We argue that none of them, at least from an American moral perspective, provides a one-size-fits-all definition of or methodology for securing fairness that could inform or standardize fairness over the universe of use cases witnessing machine learning applications. Instead, we argue that because fairness comprehensions and applications reflect a vast range of use contexts, model developers and clinician users will need to engage in thoughtful collaborations that examine how fairness should be conceived and operationalized in the use case at issue. Part II of this paper illustrates key moments in these collaborations, especially when inter and intra disagreement occurs among model developer and clinician user groups over whether a model is fair or unfair. We conclude by noting that these collaborations will likely occur over the lifetime of a model if its claim to fairness is to advance beyond "afterthought" status.

Identifiers

PMID37983258
PMCPMC10659157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.